Page 218 - 2021_09-Haematologica-web

Letters to the Editor
References
1. Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232-2273.
2. Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refrac- tory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4205 patients in Sweden. Blood Cancer J. 2021; 11(1):9.
3. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
4. Kridel R, Steidl C, Gascoyne RD. Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica. 2015;100(2):143-145.
5. Mosser DM. The many faces of macrophage activation. J Leukoc
Biol. 2003;73(2):209-212.
6. Andersen MN, Abildgaard N, Maniecki MB, Møller HJ, Andersen NF.
Monocyte/macrophage-derived soluble CD163: a novel biomarker
in multiple myeloma. Eur J Haematol. 2014;93(1):41-47.
7. Nederby L, Roug AS, Knudsen SS, et al. Soluble CD163 as a prognos- tic biomarker in B-cell chronic lymphocytic leukemia. Leuk
Lymphoma. 2015;56(11):3219-3221.
8. Wada N, Zaki MAA, Hori Y, et al. Tumour-associated macrophages
in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma
Study Group. Histopathology. 2012;60(2):313-319.
9. Leppä S, Jørgensen J, Tierens A, et al. Patients with high-risk DLBCL
benefit from dose-dense immunochemotherapy combined with
early systemic CNS prophylaxis. Blood Adv. 2020;4(9):1906-1915. 10. Glimelius B, Melin B, Enblad G, et al. U-CAN: a prospective longitu- dinal collection of biomaterials and clinical information from adult
cancer patients in Sweden. Acta Oncol. 2018;57(2):187-194.
11. Autio M, Leivonen S, Brück O, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell
lymphoma. Haematologica. 2021; 106(3):718-729.
12. Møller HJ. Soluble CD163. Scand J Clin Lab Invest. 2012;72(1):1-13. 13. Sun N, Zhao J, Qiao W, Wang T. Predictive value of interim PET/CT
in DLBCL treated with R-CHOP: meta-analysis. Biomed Res Int.
2015;2015:648572.
14. Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measure-
ments as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845-2853.
2506
haematologica | 2021; 106(9)